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Abstract: BACKGROUND: The Transcatheter Valve Therapy (TVT) registry model was recently devel-
oped to predict the risk of in-hospital mortality in patients undergoing transcatheter aortic valve replace-
ment. We sought to externally validate the model in an independent data set of consecutively enrolled
patients in the Swiss Transcatheter Aortic Valve Implantation registry. METHODS AND RESULTS:
The original prediction model was retrospectively applied to 3491 consecutive patients undergoing tran-
scatheter aortic valve replacement in Switzerland between February 2011 and February 2016. We exam-
ined model performance in terms of discrimination (Harrel C index) and calibration (Hosmer-Lemeshow
goodness-of-fit test) for prediction of in-hospital and 30-day mortality and compared its predictive accu-
racy with the Society of Thoracic Surgeons Predicted Risk of Mortality score. Rates of in-hospital and
30-day mortality in the external validation cohort were 2.9% and 3.8%, respectively. The TVT registry
model was found to have moderate discrimination (C index, 0.66; 95% confidence interval, 0.60-0.72 and
C index, 0.67; 95% confidence interval, 0.62-0.72 for in-hospital and 30-day mortality, respectively) and
good calibration. Compared with the Society of Thoracic Surgeons Predicted Risk of Mortality score, the
TVT registry model demonstrated improved calibration for in-hospital (slope, 0.83; P=0.23 versus slope,
0.24; P<0.001, respectively) and 30-day (slope, 1.11; P=0.40 versus slope, 0.41; P<0.001, respectively)
mortality. CONCLUSIONS: In a large, multicenter, non-US cohort of patients with transcatheter aortic
valve replacement, the validation of the TVT registry model demonstrated moderate discrimination and
good calibration for the prediction of in-hospital and 30-day mortality. As a result, the TVT registry
model should be considered an alternative to the Society of Thoracic Surgeons Predicted Risk of Mortal-
ity score for decision making and assessment of early outcome in patients eligible for transcatheter aortic
valve replacement.
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1Fostered by refinements in device technology, improved imaging, and streamlining of the procedure, transcatheter 
aortic valve replacement (TAVR) plays an increasingly impor-
tant role in the treatment of severe, symptomatic aortic ste-
nosis.1,2 A decline in periprocedural complications propelled 
expansion of TAVR to intermediate- and low-risk patients and 
has shifted the focus of ongoing investigations to determinants 
of long-term outcome. Risk scoring systems are instrumen-
tal to balance the expected benefits against the probability of 
adverse events and represent a useful tool to properly inform 
physicians, counsel patients, and optimize the allocation of 
healthcare resources. In the absence of a dedicated risk score 
Background—The Transcatheter Valve Therapy (TVT) registry model was recently developed to predict the risk of in-
hospital mortality in patients undergoing transcatheter aortic valve replacement. We sought to externally validate the 
model in an independent data set of consecutively enrolled patients in the Swiss Transcatheter Aortic Valve Implantation 
registry.
Methods and Results—The original prediction model was retrospectively applied to 3491 consecutive patients undergoing 
transcatheter aortic valve replacement in Switzerland between February 2011 and February 2016. We examined model 
performance in terms of discrimination (Harrel C index) and calibration (Hosmer–Lemeshow goodness-of-fit test) 
for prediction of in-hospital and 30-day mortality and compared its predictive accuracy with the Society of Thoracic 
Surgeons Predicted Risk of Mortality score. Rates of in-hospital and 30-day mortality in the external validation cohort 
were 2.9% and 3.8%, respectively. The TVT registry model was found to have moderate discrimination (C index, 0.66; 
95% confidence interval, 0.60–0.72 and C index, 0.67; 95% confidence interval, 0.62–0.72 for in-hospital and 30-
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Mortality score, the TVT registry model demonstrated improved calibration for in-hospital (slope, 0.83; P=0.23 versus 
slope, 0.24; P<0.001, respectively) and 30-day (slope, 1.11; P=0.40 versus slope, 0.41; P<0.001, respectively) mortality.
Conclusions—In a large, multicenter, non-US cohort of patients with transcatheter aortic valve replacement, the 
validation of the TVT registry model demonstrated moderate discrimination and good calibration for the prediction 
of in-hospital and 30-day mortality. As a result, the TVT registry model should be considered an alternative to the 
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2  Pilgrim et al  External Validation of the TVT Registry Model
for TAVR, the Society of Thoracic Surgeons Predicted Risk of 
Mortality (STS-PROM) and the System for Cardiac Operative 
Risk Evaluation are routinely integrated in the heart team 
evaluation of patients with symptomatic severe aortic stenosis. 
However, both scores have been derived from cohorts of surgi-
cal patients; the extrapolation to patients with TAVR remains, 
therefore, challenging and their suitability arguable.3,4 In 
recent years, several attempts to develop TAVR-specific risk 
models have been performed.5–10 However, the majority of 
these novel scores have not been validated in external cohorts, 
limiting their adoption in clinical practice. Because prediction 
models are conceived to be applied to future patients, their 
value depends on the performance shown outside the develop-
ment sample. To date, the Transcatheter Valve Therapy (TVT) 
registry model represents the score that has been derived from 
the largest cohort of patients with TAVR including 13 718 par-
ticipants of the STS/American College of Cardiology TVT 
registry.11
The aim of this study was to evaluate the extent of gen-
eralizability of the TVT registry model by quantifying its 
performance in an independent data set. For this purpose, we 
investigated its prediction accuracy in patients included in the 
prospective Swiss Transcatheter Aortic Valve Implantation 
(TAVI) registry.
Methods
Participants
The external validation cohort included all patients with severe na-
tive aortic valve stenosis who were consecutively treated and entered 
into the Swiss TAVI registry (NCT01368250) between February 
2011 and February 2016. The details of the rationale and design of 
the Swiss TAVI registry have been described previously.12 In brief, 
the Swiss TAVI registry is a nationwide registry that prospectively 
collects clinical and procedural data of patients undergoing TAVR 
with CE-marked devices in Switzerland with regular follow-up at 
30 days, 1 year, and yearly thereafter. A dedicated clinical commit-
tee is responsible for the adjudication of the clinical events occur-
ring during the index hospitalization or at follow-up according to the 
definitions of the Valve Academic Research Consortium-2 criteria.13 
The registry has been approved by the local ethics committee of all 
recruiting centers, and all patients provided written informed con-
sent to participate.
Measurements
The TVT registry model was applied through the automatic calcu-
lator accessible online at http://tools.acc.org/TAVRRisk/. The model 
includes the following variables: (1) age at admission; (2) estimated 
glomerular filtration rate, calculated on the basis of age, sex, race, 
preprocedure creatinine, and requirement of preprocedure dialysis; 
(3) hemodialysis or peritoneal dialysis on an ongoing basis as a result 
of renal failure; (4) New York Heart Association functional class IV, 
defined as cardiac disease with dyspnea at rest that increases with any 
physical activity, resulting in inability to perform any physical ac-
tivity without discomfort; (5) history of severe chronic lung disease, 
defined as forced expired volume in 1 second <50% predicted and 
room air p02 <60 or room air Pco2 >50; (6) nonfemoral access site; (7) acuity status 2 defined as urgent procedure status plus no prepro-
cedure shock, inotropes, mechanical assist device, or cardiac arrest; 
(8) acuity status 3 defined as elective or urgent procedure status plus 
preprocedure shock, inotropes, or mechanical assist device plus no 
prior cardiac arrest within 24 hours of procedure; (9) acuity status 
4 defined as emergency or salvage procedure or prior cardiac arrest 
within 24 hours of operation. Definitions used in the Swiss TAVI and 
the TVT registry were similar with respect to the variables used in the 
model. Specifically, our registry records age at admission, dialysis 
status, New York Heart Association functional class, severe chronic 
lung disease, and femoral access. Glomerular filtration rate was cal-
culated according to the modification of diet in renal disease equation 
and presence of dialysis. Because acuity categories are not included 
in the Swiss TAVI registry variables, we derived acuity status (2, 3, or 
4) by matching the setting of the procedure (elective or urgent) and 
hemodynamic status (cardiogenic shock).
The present study complies with the Transparent Reporting of a 
Multivariable Prediction Model for Individual Prognosis or Diagnosis 
guidelines for the reporting of studies that validate prediction scores 
(Table I in the Data Supplement).14
Statistical Analysis
Patient baseline characteristics were expressed as means and SD or 
frequencies (percentage). Validation of the TVT registry model was 
performed by examining measures of discrimination and calibration. 
Discrimination describes the power of models to distinguish patients 
who have events (death) from those who have no events. It was as-
sessed using the C index that represents the area under the receiver 
operating characteristic curve and for which larger values are asso-
ciates with better discrimination. Calibration is a measure of how 
closely the predicted probabilities (of death) reflect the actual risk; it 
was assessed by performing the Hosmer–Lemeshow goodness-of-fit 
test and was graphically depicted in the plot of observed versus pre-
dicted mortality with a value <0.05 indicating significant difference 
in expected versus observed mortality. Calibration was also assessed 
by testing for an intercept of zero and a slope of 1 when regress-
ing observed proportion of deaths on predicted proportion of deaths 
based on the TVT. Deciles of the TVT score were used to calculate 
proportions. Although acknowledging that the TVT registry model 
was designed to predict in-hospital mortality, we additionally tested 
whether it could be predictive of mortality at 30 days after TAVR. 
Model performance in terms of calibration was also examined in pre-
specified subgroups defined by age of <85 years or older, estimated 
WHAT IS KNOWN
• Prediction models may improve the management of 
patients with severe aortic valve stenosis undergoing 
transcatheter aortic valve replacement.
• Risk scoring systems derived from surgical cohorts 
proved suboptimal performance when applied to 
transcatheter aortic valve replacement populations.
• The Transcatheter Valve Therapy registry model has 
been derived to predict in-hospital mortality after 
transcatheter aortic valve replacement with modest 
discrimination and good calibration in the develop-
ment cohort.
WHAT THE STUDY ADDS
• The predictive performance of the Transcatheter 
Valve Therapy registry model is preserved in an in-
dependent, non-US cohort of patients with transcath-
eter aortic valve replacement.
• The predictive accuracy is maintained ≤30 days after 
the procedure.
• In a comparative analysis with the Society of 
Thoracic Surgeons Predicted Risk of Mortality 
score, the Transcatheter Valve Therapy registry 
model showed better calibration for prediction of in-
hospital and 30-day mortality.
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3  Pilgrim et al  External Validation of the TVT Registry Model
glomerular filtration rate <60 mL/min, between 60 and 90 mL/min, 
or >90 mL/min, need for dialysis, New York Heart Association class 
IV or class I to III, nonfemoral access, acuity categories, and sex. 
The main analyses were repeated after multiple imputation of miss-
ing variables. In addition, we examined the predictive accuracy of the 
STS-PROM score and compared it with that of the TVT registry mod-
el using the DeLong method. The STS-PROM score was calculated 
at the time of intervention according to the models developed from 
the STS database, available at http://riskcalc.sts.org/stswebriskcalc/.
Analyses were conducted using Stata Statistical Software, Release 
14.1 (StataCorp LP, College Station, TX), and statistical significance 
was defined as P<0.05.
Results
The validation cohort comprised 3491 consecutive patients 
included into the Swiss TAVI registry between February 2011 
and February 2016. In-hospital and thirty-day survival data 
were available for the entire cohort. Rates of in-hospital and 
30-day mortality amounted to 2.9% and 3.8%, respectively. 
Table 1 summarizes the baseline clinical characteristics of 
patients who died in hospital versus those who survived. 
Male and female patients were similarly represented in either 
group. Mean STS-PROM score was 5.8±4.5, and it was sig-
nificantly higher in patients who died in hospital (7.6±5.9 
versus 5.8±4.4; P<0.001). Nonsurvivors were older compared 
with survivors (84.2±5.7 versus 82.1±6.5 years; P=0.001) and 
more often presented with renal dysfunction. In addition, non-
survivors more commonly presented with cardiogenic shock 
(5% versus 1%; P<0.001) and more often underwent urgent 
instead of elective TAVI (acuity category 2 or 4). Type of 
transcatheter heart valves used are reported in Table II in the 
Data Supplement. Overall, 43.6% of patients received early 
generation devices (Medtronic CoreValve or Edwards Sapien 
XT). The comparison between validation and development 
cohorts in terms of demographics is reported in Table III in 
the Data Supplement.
Performance of the TVT Registry Model
The performance of the TVT registry model in the Swiss TAVI 
cohort was assessed using the original coefficients that were 
obtained in the development sample. Refitted model coeffi-
cients and odds ratios with 95% confidence interval (CI) for 
each covariate in the validation cohort are reported for descrip-
tive purposes in Table IV in the Data Supplement. In the Swiss 
TAVI registry cohort, the TVT registry model showed mod-
erate discrimination, with a C index for in-hospital mortal-
ity of 0.66 and 95% CI, 0.60 to 0.72 (Figure 1A). Moreover, 
the C index for prediction of 30-day mortality was 0.67 and 
95% CI, 0.65 to 0.69 (Figure 1C). The results were consistent 
when analyzing the performance of the model among patients 
included in the Swiss TAVI registry during the same period of 
patients included in the derivation cohort (Table V in the Data 
Supplement).
Calibration plots are shown in Figure 2A and 2C. A 
close agreement between predicted versus observed mortal-
ity was documented for both in-hospital and 30-day outcome. 
Model calibration was preserved across several prespecified 
subgroups; we recorded, however, an overestimation of in-
hospital and 30-day mortality for patients on hemodialysis 
(Figure 3).
Performance of the STS-PROM Score
As shown in Figure 1B and 1D, the STS-PROM score achieved 
moderate discriminative ability for prediction of in-hospital 
Table 1. Baseline Characteristics of the Entire Validation 
Cohort and Stratified According to In-Hospital Mortality
 
All Patients Survivors
Died in 
Hospital
P Valuen=3491 n=3390 n=101
Model covariates
Age, y 82.1±6.5 82.1±6.5 84.2±5.7 0.001
STS-PROM score 5.8±4.5  5.8±4.4 7.6±5.9 0.001
Sex    0.10
  Men 1760 (50%) 1701 (50%) 59 (58%)  
  Women 1731 (50%) 1689 (50%) 42 (42%)  
Dialysis    0.27
  No 3406 (98%) 3309 (98%) 97 (96%)  
  Yes 81 (2%) 77 (2%) 4 (4%)  
Severe chronic lung 
disease
   0.52
  No 3045 (87%) 2959 (87%) 86 (85%)  
  Yes 445 (13%) 430 (13%) 15 (15%)  
NYHA functional 
class
   0.088
  I 313 (9%) 307 (9%) 6 (6%)  
  II 852 (25%) 835 (25%) 17 (17%)  
  III 1848 (54%) 1790 (54%) 58 (59%)  
  IV 401 (12%) 384 (12%) 17 (17%)  
Cardiogenic shock 
(class Killip 4)
   <0.001
  No 3457 (99%) 3361 (99%) 96 (95%)  
  Yes 34 (1%) 29 (1%) 5 (5%)  
eGFR, mL/min 63.7±26.0 63.9±26.0 55.4±24.8 0.001
Access    <0.001
  Femoral 3045 (87%) 2971 (88%) 74 (73%)  
  Transapical 357 (10%) 337 (10%) 20 (20%)  
  Subclavian 34 (1%) 32 (1%) 2 (2%)  
  Direct aortic 34 (1%) 30 (1%) 4 (4%)  
  Other 21 (1%) 20 (1%) 1 (1%)  
Acuity category    <0.001
  1 3370 (97%) 3,281 (97%) 89 (88%)  
  2 87 (2%) 80 (2%) 7 (7%)  
  4 34 (1%) 29 (1%) 5 (5%)  
  TVT score 3.9±3.1 3.9±2.9 6.1±5.7 <0.001
  STS-PROM score 4.4  
(3.0–7.0)
4.4  
(2.9–7.0)
5.4  
(3.6–10.0)
<0.001
Values are mean±SD or medians (25%–75% interquartile ranges). Definition 
of acuity categories is provided in the text. eGFR indicates estimated glomerular 
filtration rate; NYHA, New York Heart Association; STS-PROM, Society of Thoracic 
Surgeons Predicted Risk of Mortality; and TVT, transcatheter valve therapy.
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(C index, 0.61; 95% CI, 0.56–0.67) and 30-day (C index, 0.63; 
95% CI, 0.59–0.68) mortality. Figure 2B and 2D displays a 
separation between observed and predicted mortality rates, 
especially for the higher values of estimated risk.
Comparative Performance of the TVT Registry 
Model and the STS-PROM Score in the Swiss TAVI 
Registry
Tables 2 and 3 report the comparison between the predictive 
accuracy of the TVT registry model and the STS-PROM score 
in our population. C index for the prediction of in-hospital 
and 30-day mortality were 0.66 versus 0.61 (P=0.14) and 0.67 
versus 0.63 (P=0.12) for the TVT registry model and STS-
PROM score, respectively. The Hosmer–Lemeshow statistics 
showed a better calibration ability of the TVT registry model 
compared with the STS-PROM score for in-hospital (slope, 
0.83; P=0.23 versus slope, 0.24; P<0.001, respectively) and 
30-day (slope, 1.11; P=0.40 versus slope, 0.41; P<0.001, 
respectively) mortality. Discrimination of the TVT registry 
model and STS-PROM score after multiple imputation of 
missing variables yielded comparable results (Table VI in the 
Data Supplement).
Discussion
The main findings of our study validating the performance of 
the TVT registry model in a large cohort of patients undergo-
ing TAVR at multiple centers in Switzerland can be summa-
rized as follows: (1) the TVT registry model showed moderate 
discrimination and adequate calibration for the prediction of 
in-hospital mortality after TAVR, (2) its predictive accuracy 
was maintained for mortality at 30 days, and (3) the TVT reg-
istry model showed significantly better predictive accuracy in 
terms of calibration as compared with the STS-PROM score, 
whereas discrimination was comparable.
The TVT registry model has been recently developed to 
predict in-hospital mortality in a cohort of >13 000 patients 
undergoing TAVR in the United States between 2011 and 
2014. The internal validation cohort comprised >6000 patients 
treated between March and October 2014. The model showed 
moderate discrimination with a C index of 0.67 (95% CI, 
0.65–0.69) in the development group and 0.66 (95% CI, 0.62–
0.69) in the validation group, respectively, and good calibra-
tion. Although alternative scores have been both derived and 
validated in relatively small cohorts, the TVT registry model 
has been derived and validated in a cohort surpassing the 
Figure 1. Receiving operating characteristic curve for prediction of in-hospital and 30-day mortality of the Transcatheter Valve Therapy 
(TVT) registry model (A and C) and the Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) score (B and D). CI indi-
cates confidence interval.
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next largest cohort used to build a risk score by a factor of 5. 
The time interval of patients included in the present analy-
sis largely corresponded with the time interval of the STS/
American College of Cardiology TVT registry. In our study, 
we found a discrimination of the TVT registry model for the 
prediction of in-hospital mortality comparable with the origi-
nal report; moreover, discrimination was maintained at 30 
days after the procedure. This clearly defined time window 
allows for a better assessment of early outcomes after TAVR 
because in-hospital length of stay may be highly variable 
across different centers.
A risk–benefit analysis is an integral part of the Heart 
Team assessment for the selection of the optimal treat-
ment strategy for patients with severe aortic valve steno-
sis. Clinical and anatomic characteristics complement the 
multidisciplinary evaluation of the patient and are consoli-
dated in specific scores quantifying periprocedural risk. 
Risk scores allow for the possibility of comparing health 
across different populations. Several risk scores have proven 
instrumental for surgical procedures and are regularly har-
monized with updated information on contemporary event 
rates. In the absence of a tailored risk score for TAVR, risk 
models originally derived from surgical cohorts have been 
used for the definition of risk categories and patient selec-
tion in randomized trials of TAVR versus surgical aortic 
valve replacement.15–17 However, there is a large body of 
evidence demonstrating a suboptimal performance of such 
scores in TAVR cohorts. Indeed, in the PARTNER I trial 
(Placement of Aortic Transcatheter Valves) and continued 
access registry, both the STS-PROM score and the Logistic 
System for Cardiac Operative Risk Evaluation overesti-
mated the mortality occurring in-hospital or at 30 days after 
TAVR.3 Along the same line, in a retrospective analysis of 
patients treated with the Medtronic CoreValve prosthesis at 
2 European centers, both the Logistic System for Cardiac 
Operative Risk Evaluation and the STS-PROM algorithm 
were found to have suboptimal discriminatory power and 
calibration.4 Consistently, in our cohort, the STS-PROM 
score showed poorer calibration among patients with higher 
estimated mortality risk. This finding does not only pertain 
to the field of TAVR but has already been reported in surgical 
series.18Arguably, such suboptimal calibration in high-risk 
categories may stem from high mortality rates in the original 
derivation cohort of the STS-PROM score.
Figure 2. Calibration plots showing the predicted (x axis) probability vs observed (y axis) in-hospital and 30-day mortality after trans-
catheter aortic valve replacement for the Transcatheter Valve Therapy (TVT) registry model (A and C, respectively) and the Society 
of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) score (B and D). The diagonal line represents the perfect calibration 
(observed=calibration). Observed mortality is represented with 95% confidence intervals (error bars).
 by guest on D
ecem
ber 13, 2017
http://circinterventions.ahajournals.org/
D
ow
nloaded from
 
6  Pilgrim et al  External Validation of the TVT Registry Model
More recently, several TAVR-specific risk scores have 
been suggested, as summarized in Table 4. Most scores have 
been validated for 30-day mortality and were found to have 
a C index ranging from 0.57 to 0.75. Although applicability 
of both the STS-PROM score and the System for Cardiac 
Operative Risk Evaluation has been repeatedly questioned in 
view of their derivation and validation in patients with surgi-
cal access, the TVT risk model is the first among the specific 
TAVR risk scores to differentiate between transfemoral and 
alternative (surgical) approach for TAVR.
Currently available risk scores for TAVR are limited 
by several factors. Time is an important covariable rarely 
accounted for in conventional risk scores. A discount in risk 
over time has been observed for the STS-PROM score result-
ing in a reclassification of more than half of patients originally 
deemed to be high risk to intermediate risk in  an analysis 
repeated 6 to 7 years after the first analysis.19 Sensitive scores 
work bidirectionally: they inform about anticipated risk, while 
regularly being updated by the most recent outcome data. This 
may be particularly important in a rapidly evolving field, such 
as TAVR, where device iterations have been shown to sub-
stantially reduce periprocedural complications as reflected 
by a large heterogeneity of reported outcomes across major 
studies. Moreover, deficiencies of standard modelling meth-
ods, relatively small and homogenous derivation cohorts, and 
absence of validation in external datasets further hamper the 
robustness of existing TAVR risk scores. To date, there were 
no studies assessing the reproducibility and transportability 
of the TVT registry model. Geographical variability in per-
formance is mainly related to variation in case mix, that is 
dissimilarity between patients in different countries.20 In our 
study, the predictive accuracy of the TVT registry model was 
confirmed in an unselected cohort of consecutive patients 
treated in Switzerland. The reproducibility of the results 
observed in the development cohort is an important finding 
in view of the expected differences between the 2 sides of 
the Atlantic in terms of patient features, devices, procedural 
characteristics, and postprocedural care. Some concerns may 
arise about model performance because its discrimination was 
Figure 3. Observed (closed circle) vs predicted (open circle) in-hospital and 30-day mortality across prespecified subgroups. COPD indi-
cates chronic obstructive pulmonary disease; eGFR, glomerular filtration rate; and NYHA, New York Heart Association.
Table 2. Discrimination of the TVT Registry Model and the 
STS-PROM Score
 AUC (95% CI)
 TVT Registry Model vs 
STS-PROM Score
P Value
In-hospital mortality  0.14
  TVT registry model 0.66 (0.60–0.72)  
  STS-PROM score 0.61 (0.56–0.67)  
30-d mortality 0.12
  TVT registry model 0.67 (0.62–0.72)  
  STS-PROM score 0.63 (0.59–0.68)  
AUC indicates area under the receiver operating characteristic curve; CI, 
confidence interval; STS-PROM, Society of Thoracic Surgeons Predicted Risk of 
Mortality; and TVT, transcatheter valve therapy.
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only moderate in the original and current cohorts. However, 
this limitation is counterbalanced at least, in part, by the good 
calibration that was confirmed in this external cohort and 
preserved across several subgroups of patients. This prop-
erty ensures high reliability in counseling patients and their 
relatives about the risk of death early after the procedure. At 
this regard, the considerable gain in terms of calibration of 
the TVT registry model compared with the STS-PROM score 
could have important clinical implications, especially when 
dealing with patients at the extremes of risk categories where 
the reliability of the STS-PROM score is poorer.
Limitations
We acknowledge the following limitations of our study: (1) 
although we were able to include a large contemporary TAVR 
population with excellent documentation of baseline and 
Table 3. Calibration of the TVT Registry Model and the STS-PROM Score
 
Hosmer–Lemeshow  
Test (P Value) Intercept P Value* Slope P Value†
TVT registry model
  In-hospital mortality 0.15 −0.00 (−0.02 to 0.01) 0.517 0.83 (0.58–1.08) 0.23
  30-d mortality 0.36 −0.01 (−0.02 to 0.01) 0.323 1.11 (0.87–1.34) 0.40
STS-PROM score
  In-hospital mortality 0.58 0.01 (0.01–0.02) 0.006 0.24 (0.14–0.35) <0.001
  30-d mortality 0.58 0.01 (0.01–0.02) 0.003 0.41 (0.32–0.50) <0.001
STS-PROM indicates Society of Thoracic Surgeons Predicted Risk of Mortality; and TVT, transcatheter valve therapy.
*Null hypothesis, calibration plot intercept=0.
†Null hypothesis, calibration plot slope=1.
Table 4. Main Features of the Currently Available TAVI Risk Scores
Score  
(Author, Year)
FRANCE-2  
(Iung, 2014)6
TARIS (Seiffert, 
2014)5
OBSERVANT 
(Capodanno, 
2014)8
Predictor of Poor 
Outcomes (Arnold  
et al, 2014)9
TAVI
2
  
(Debonnaire, 
2015)7
CoreValve 
US Program 
(Hermiller, 2016)10
TVT Registry 
Model (Edwards, 
2016)11
Population FRANCE-2 
registry; derivation 
cohort, n=2552; 
validation cohort, 
n=1281
GARY registry; 
derivation cohort, 
n=845; validation 
cohort, n=333
OBSERVANT 
study derivation 
cohort, n= 1256; 
validation cohort, 
n=622
PARTNER program; 
derivation cohort, 
n=1420; validation 
cohort, n=717
Patients treated 
at 2 centers (the 
Netherlands and 
Italy); derivation 
cohort, n=511
Medtronic 
CoreValve US 
Pivotal trial; 
derivation 
cohort, n=2482; 
validation cohort, 
n=1205
STS/ACC TVT 
registry; derivation 
cohort, n=13718; 
validation cohort, 
n=6868
Variables BMI <30; 
NYHA class 
IV; respiratory 
insufficiency; 
pulmonary 
hypertension; 
≥2 episodes 
of pulmonary 
edema during 
past year; critical 
hemodynamic 
state; dialysis
BMI; eGFR; 
hemoglobin; 
pulmonary 
hypertension; 
mean 
transvalvular 
gradient; LVEF
GFR <45 mL/
min; critical 
preoperative state; 
NYHA class IV; 
pulmonary artery 
hypertension; 
diabetes mellitus; 
prior BAV; LVEF 
<40%
Male sex; diabetes 
mellitus; major 
arrhythmia; serum 
creatinine; mean 
arterial pressure; 
body mass index; 
oxygen-dependent 
lung disease; mean 
aortic valve gradient; 
mini–mental status 
examination; 6-min 
walk test distance
Age >85 y; men; 
porcelain aorta; 
recent MI (<90 
d); CrCl <30 
mL·kg−1·min−1; 
hemoglobin <10 
g/dL; LVEF <35%; 
baseline AVMG 
≥70 mm Hg
Albumin ≤3.3 g/
dL; assisted living; 
home oxygen; age 
>85 y. Albumin 
≤3.3 g/dL; Seve 
Charlson score; 
home oxygen; STS 
>7%
Age; NYHA 
class IV; chronic 
lung disease 
(severe); acuity 
(3 levels); dialysis 
or glomerular 
filtration rate; 
nonfemoral 
approach
Predicted 
Outcomes
30-d mortality 30-d mortality 30-d mortality Death, KCCQ-OS 
score <45, or 
≥10-point decrease 
in KCCQ-OS score 
compared with 
baseline at 6 mo 
and 1 y
1-y mortality 30-d mortality; 
1-y mortality
In-hospital 
mortality
C index 0.67 0.57 0.71 0.66 0.71 0.75  
(30 d); 0.79 (1 y)
0.66
ACC indicates American College of Cardiology; AVMG, aortic valve mean gradient; BAV, balloon aortic valvuloplasty; BMI, body mass index; eGFR, estimated glomerular 
filtration rate; FRANCE-2, French Aortic National CoreValve and Edwards Registry; GARY, German Aortic Valve Registry; KCCQ-OS, Kansas City Cardiomyopathy 
Questionnaire–Overall Summary Scale; LVEF, left ventricular ejection fraction; MI, myocardial infraction; NYHA, New York Heart Association; OBSERVANT, Observational 
Study of Approriateness, Efficacy and Effectiveness of AVR-TAVR Procedures for the Treatment of Severe Symptomatic Aortic Stenosis; PARTNER, placement of aortic 
transcatheter valves; STS, Society of Thoracic Surgeons; TARIS, TAVI Risk Score; TAVI, transcatheter aortic valve implantation; and TVT, transcatheter valve therapy.
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follow-up status, the TVT registry model was validated in a 
retrospective manner; (2) we were unable to assess the added 
value of indices of frailty and measures of quality of life that 
were not included in the original model because they are not 
systematically collected in our database; (3) the results of our 
validation analysis may be affected by the impossibility to 
quantify the case-mix differences between development and 
validation samples because, with the exception of age and 
sex, no other baseline clinical characteristics of the original 
cohort were available; (4) although predicted versus observed 
mortality was consistent for both in-hospital and 30-day out-
comes across several subgroups, an overestimation of in-
hospital and 30-day mortality for patients on hemodialysis 
was observed. This should be carefully interpreted in view of 
multiple testing and the small number of patients included in 
this subgroup; (5) we were unable to assess the comparative 
performance of the TVT registry model and other risk scores 
because measures such as frailty, mini–mental status exami-
nation, 6-minute walk test distance, assisted living, home 
oxygen use, and Charlson Comorbidity Index are not system-
atically collected in our database; (6) in view of the ongoing 
expansion of TAVR adoption in lower-risk patients, further 
studies are needed to validate the accuracy of this model in 
low-risk populations.
Conclusions
In a large, multicenter, non-US cohort of patients with TAVR, 
the validation of the TVT registry model demonstrated moder-
ate discrimination and good calibration for the prediction of 
in-hospital and 30-day mortality. As a result, the TVT registry 
model should be considered an alternative to the STS-PROM 
score for decision making and assessment of early outcome in 
patients eligible for TAVR.
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Supplemental Table 1. TRIPOD Checklist 
Section/Topic Item  Checklist Item Page 
Title and abstract 
Title 1 D;V 
Identify the study as developing and/or validating a multivariable prediction model, the 
target population, and the outcome to be predicted. 
1 
Abstract 2 D;V 
Provide a summary of objectives, study design, setting, participants, sample size, 
predictors, outcome, statistical analysis, results, and conclusions. 
2 
Introduction 
Background 
and objectives 
3a D;V 
Explain the medical context (including whether diagnostic or prognostic) and rationale 
for developing or validating the multivariable prediction model, including references to 
existing models. 
3 
3b D;V 
Specify the objectives, including whether the study describes the development or 
validation of the model or both. 
3 
Methods 
Source of data 
4a D;V 
Describe the study design or source of data (e.g., randomized trial, cohort, or registry 
data), separately for the development and validation data sets, if applicable. 
4 
4b D;V 
Specify the key study dates, including start of accrual; end of accrual; and, if applicable, 
end of follow-up.  
4 
Participants 
5a D;V 
Specify key elements of the study setting (e.g., primary care, secondary care, general 
population) including number and location of centres. 
4 
5b D;V Describe eligibility criteria for participants.  4 
5c D;V Give details of treatments received, if relevant.  4 
Outcome 
6a D;V 
Clearly define the outcome that is predicted by the prediction model, including how and 
when assessed.  
4-5 
6b D;V Report any actions to blind assessment of the outcome to be predicted.  N.A. 
Predictors 
7a D;V 
Clearly define all predictors used in developing or validating the multivariable prediction 
model, including how and when they were measured. 
4-5 
7b D;V 
Report any actions to blind assessment of predictors for the outcome and other 
predictors.  
N.A. 
Sample size 8 D;V Explain how the study size was arrived at. N.A. 
Missing data 9 D;V 
Describe how missing data were handled (e.g., complete-case analysis, single 
imputation, multiple imputation) with details of any imputation method.  
5. 
Statistical 
analysis 
methods 
10a D Describe how predictors were handled in the analyses.  N.A. 
10b D 
Specify type of model, all model-building procedures (including any predictor selection), 
and method for internal validation. 
5 
10c V For validation, describe how the predictions were calculated.  5 
10d D;V 
Specify all measures used to assess model performance and, if relevant, to compare 
multiple models.  
5-6 
10e V Describe any model updating (e.g., recalibration) arising from the validation, if done. N.A. 
Risk groups 11 D;V Provide details on how risk groups were created, if done.  5 
Development 
vs. validation 
12 V 
For validation, identify any differences from the development data in setting, eligibility 
criteria, outcome, and predictors.  
N.A. 
Results 
Participants 
13a D;V 
Describe the flow of participants through the study, including the number of participants 
with and without the outcome and, if applicable, a summary of the follow-up time. A 
diagram may be helpful.  
6. 
13b D;V 
Describe the characteristics of the participants (basic demographics, clinical features, 
available predictors), including the number of participants with missing data for 
predictors and outcome.  
6 
13c V 
For validation, show a comparison with the development data of the distribution of 
important variables (demographics, predictors and outcome).  
N.A. 
Model 
development  
14a D Specify the number of participants and outcome events in each analysis.  6 
14b D 
If done, report the unadjusted association between each candidate predictor and 
outcome. 
Supplemental 
Table 2 
Model 
specification 
15a D 
Present the full prediction model to allow predictions for individuals (i.e., all regression 
coefficients, and model intercept or baseline survival at a given time point). 
6 
15b D Explain how to the use the prediction model. 10 
Model 
performance 
16 D;V Report performance measures (with CIs) for the prediction model. 
6 and Figure 1 
and 2 
Model-updating 17 V 
If done, report the results from any model updating (i.e., model specification, model 
performance). 
N.A. 
Discussion 
Limitations 18 D;V 
Discuss any limitations of the study (such as nonrepresentative sample, few events per 
predictor, missing data).  
10 
Interpretation 
19a V 
For validation, discuss the results with reference to performance in the development 
data, and any other validation data.  
9 
19b D;V 
Give an overall interpretation of the results, considering objectives, limitations, results 
from similar studies, and other relevant evidence.  
8-10 
Implications 20 D;V Discuss the potential clinical use of the model and implications for future research.  8-10 
Other information 
Supplementary 
information 
21 D;V 
Provide information about the availability of supplementary resources, such as study 
protocol, Web calculator, and data sets.  
N.A 
Funding 22 D;V Give the source of funding and the role of the funders for the present study.  N.A. 
     Supplemental Table 2. Type and frequency of transcatheter heart 
valves in the Swiss TAVI cohort 
  All patients Survivors Died in hospital 
  n= 3,491 n= 3,390 n= 101 
Medtronic CoreValve 917 (26%) 892 (26%) 25 (25%) 
Edwards Sapien XT 606 (17%) 582 (17%) 24 (24%) 
Symetis Acurate 98  (3%) 96  (3%) 2  (2%) 
JenaValve 57  (2%) 53  (2%) 4  (4%) 
SJM Portico 87  (3%) 85  (3%) 2  (2%) 
Medtronic Engager 2  (0%) 1  (0%) 1  (1%) 
Direct Flow Medical 34  (1%) 33  (1%) 1  (1%) 
Edwards Sapien 3 1163 (33%) 1131 (33%) 32 (32%) 
BSC Lotus 186  (5%) 186  (6%) 0  (0%) 
Medtronic Evolut R 330  (9%) 321  (9%) 9  (9%) 
   Supplemental Table 3. Baseline clinical characteristics of patients in the validation 
and development cohorts 
  SWISS TAVI Registry STS/ACC TVT Registry 
  n= 3491 n= 13718 
Age (years) 82.1 ±  6.5 82.1 ±  8.3 
Male gender (%) 1760 (50%) 6680 (48.7%) 
Values are mean ± SD or percentages. 
 
 
 
 
 
 Refitted coefficients are shown for descriptive purpose only. Original coefficients were used to assess 
the predictive performance of the TVT Registry model in the external validation cohort. Missing data 
was imputed using chained equations to generate 20 imputations sets. Estimates were combined using 
Rubin's rule.  No acuity category 3 patients defined. eGFR, Estimated glomerular filtration rate; NYHA, 
New York Heart Association. 
 
 
 
 
 
 
 
 
 
Supplemental Table 4. Univariable and multivariable predictors of mortality rates from the external 
validation cohort 
  
Unadjusted  
OR (95% CI) 
p 
value 
  
Adjusted  
OR (95% CI) 
p 
value 
 
In-hospital mortality 
          
Age (5 year intervals) 1.36 (1.13 - 1.63) 0.001   1.41 (1.16 - 1.71) 0.001 
GFR (5-U increments) 0.91 (0.87 - 0.95) <0.001   0.92 (0.87 - 0.98) 0.005 
Dialysis 1.77 (0.64 - 4.94) 0.27   1.20 (0.38 - 3.79) 0.76 
NYHA class IV 1.60 (0.94 - 2.73) 0.083   1.04 (0.58 - 1.89) 0.89 
Severe chronic lung disease 1.20 (0.69 - 2.10) 0.52   1.30 (0.73 - 2.33) 0.37 
Non femoral access 2.59 (1.65 - 4.07) <0.001   2.97 (1.86 - 4.73) <0.001 
Acuity category 2 3.08 (1.39 - 6.85) 0.006   3.25 (1.41 - 7.52) 0.006 
Acuity category 4 6.04 (2.29 - 15.93) <0.001   6.20 (1.90 - 20.24) 0.003 
            
30 day mortality           
Age (5 year intervals) 1.34 (1.14 - 1.58) <0.001   1.39 (1.17 - 1.64) <0.001 
GFR (5-U increments) 0.89 (0.85 - 0.93) <0.001   0.90 (0.86 - 0.95) <0.001 
Dialysis 2.08 (0.89 - 4.87) 0.091   1.15 (0.44 - 3.03) 0.78 
NYHA class IV 1.39 (0.85 - 2.26) 0.191   0.79 (0.45 - 1.38) 0.40 
Severe chronic lung disease 1.31 (0.81 - 2.11) 0.27   1.47 (0.89 - 2.41) 0.13 
Non femoral access 2.48 (1.66 - 3.72) <0.001   2.80 (1.85 - 4.25) <0.001 
Acuity category 2 2.30 (1.04 - 5.07) 0.04   2.45 (1.07 - 5.63) 0.034 
Acuity category 4 8.27 (3.67 - 18.64) <0.001   8.56 (3.06 - 23.89) <0.001 
      
 Supplemental Table 5. Performance of the TVT Registry Model across different 
time periods 
  AUC (95% CI) χ²* p value* 
November 2011- February 2014 (N = 1317) 
In-hospital death 0.68 (0.59 - 0.76) 11.51 0.174 
30 day death 0.68 (0.61 - 0.75) 7.59 0.475 
March 2014-February 2016 (N = 2174) 
In-hospital death 0.63 (0.54 -0.71) 4.2 0.839 
30 day death 0.66 (0.59 - 0.73) 2.97 0.936 
November 2011- February 2014 corresponds to the same time period of the derivation cohort.  *Hosmer-Lemeshow test. 
**Combination of Chi² statistics in MI result in values from an F distribution. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
Supplemental Table 6. Model fit statistics after multiple 
imputation of missing variables  
         
   AUC (95% CI) 
 
p value* 
         
 TVT Registry Model       
 In-hospital mortality 0.66 (0.60 - 0.71)   0.25 
 30-day mortality 0.68 (0.63 - 0.73)   0.46 
     
STS-PROM score   
  In-hospital mortality 0.61 (0.56 - 0.67)   0.63 
 30-day mortality 0.64 (0.59 - 0.68)   0.56 
 Combination of Chi² statistics in MI result in values from an F distribution. 
*Hosmer-Lemeshow test. The following variables were imputed: age(0.26% of 
cases), estimated glomerular  filtration rate (0.43%), dialysis (0.11%), NYHA class 
4 (2.21%). 
 
  
 
